Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer

E. Bria, P. Visca, F. Novelli, B. Casini, M. G. Diodoro, R. Perrone-Donnorso, C. Botti, I. Sperduti, F. Facciolo, M. Milella, F. L. Cecere, F. Cognetti, M. Mottolese

Research output: Contribution to journalArticlepeer-review


Aim: Survivin is a member of the inhibitors of apoptosis (IAP) gene family that acts through pathways different from those involving the bcl-2 family. Largely undetectable in normal adult tissues, survivin is deregulated in most human cancers including non-small-cell lung cancer (NSCLC) and may represent a tumor marker with prognostic and therapeutic implications. Aim of our study was to determine the prognostic role of survivin as an apoptosis-related biomarker in a series of resected NSCLC patients. Methods: A retrospective series of resected NSCLC patients were retrieved from the files of the Regina Elena National Cancer Institute. Survivin was detected by immunohistochemistry (IHC) using a polyclonal antibody. Survivin displayed two kinds of immunoreactivity: (i) a diffuse cytoplasmic staining and (ii) a distinct nuclear staining. A score-scale to distinguish positive (score 1-2) vs. negative (score 0) pattern was applied. Clinical and biological (nuclear and cytoplasmic survivin staining) covariables were screened for a prognostic relationship with overall survival (OS) and disease-free survival (DFS) into the univariate and multivariate analyses. Results: Data referring to 116 NSCLC patients who underwent surgery for stage I-IIIA NSCLC were collected. Multivariate analyses identified tumor size, nodal status and nuclear, but not cytoplasmic, expression of survivin as significant independent predictors of OS, with a hazard ratio of 2.40 (95% CI 1.44, 3.99, p = 0.001), 2.03 (95% CI 1.26, 3.26, p = 0.003) and 1.83 (95% CI 1.01, 3.30, p = 0.044), respectively. Median OS for nuclear survivin positive (score 1-2) and negative (score 0) patients were 23 months (95% CI 15, 31) and 36 months (95% CI 1, 76), respectively (p = 0.01); five-year survival for score 1-2 and score 0 patients were 20% and 44.5%, respectively. Conversely, no significant impact on survival is found when patients are stratified according to cytoplasmic survivin expression. Conclusions: Data presented herein open the issue that prognosis of stage I-IIIA NSCLC can be linked to the cellular pattern of distribution of survivin.

Original languageEnglish
Pages (from-to)593-598
Number of pages6
JournalEuropean Journal of Surgical Oncology
Issue number5
Publication statusPublished - May 2008


  • Lung cancer
  • Survival
  • Survivin

ASJC Scopus subject areas

  • Oncology
  • Surgery


Dive into the research topics of 'Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this